A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Purpose

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: - How EoE makes one feel - EoE symptoms - How EoE affects quality-of-life - How EoE impacts aspects of daily life - How difficult it is to swallow - How EoE symptoms have changed throughout the study

Condition

  • Eosinophilic Esophagitis (EoE)

Eligibility

Eligible Ages
Over 12 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Initiating treatment with DUPIXENT® for EoE according to the USPI 2. Able to understand and complete registry-related questionnaires (including adolescents)

Exclusion Criteria

  1. Patients who have a contraindication to DUPIXENT® according to the USPI 2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment 3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator) NOTE: Other protocol defined inclusion/exclusion criteria apply

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
EoE Patients treated with DUPIXENT®
  • Drug: dupilumab
    No investigational agents will be provided. Dupilumab will be prescribed as per usual clinical practice and will not be provided by the sponsor.
    Other names:
    • DUPIXENT®
    • REGN668
    • SAR231893

Recruiting Locations

Vanderbilt University Medical Center
Nashville 4644585, Tennessee 4662168 37232

More Details

Status
Recruiting
Sponsor
Regeneron Pharmaceuticals

Study Contact

Clinical Trials Administrator
844-734-6643
clinicaltrials@regeneron.com

For general questions about clinical trials, contact Research Support Services at (615) 322-7343 or research.support.services@vumc.org